- Home
- RIGL vs SIBN Comparison
RIGL vs SIBN Comparison
Compare RIGL & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- SIBN
- Stock Information
- Founded
- RIGL 1996
- SIBN 2008
- Country
- RIGL United States
- SIBN United States
- Employees
- RIGL N/A
- SIBN N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- SIBN Medical/Dental Instruments
- Sector
- RIGL Health Care
- SIBN Health Care
- Exchange
- RIGL Nasdaq
- SIBN Nasdaq
- Market Cap
- RIGL 335.5M
- SIBN 805.4M
- IPO Year
- RIGL 2000
- SIBN 2018
- Fundamental
- Price
- RIGL $19.08
- SIBN $17.32
- Analyst Decision
- RIGL Buy
- SIBN Strong Buy
- Analyst Count
- RIGL 5
- SIBN 5
- Target Price
- RIGL $36.40
- SIBN $24.40
- AVG Volume (30 Days)
- RIGL 212.0K
- SIBN 490.0K
- Earning Date
- RIGL 08-05-2025
- SIBN 08-04-2025
- Dividend Yield
- RIGL N/A
- SIBN N/A
- EPS Growth
- RIGL N/A
- SIBN N/A
- EPS
- RIGL 2.08
- SIBN N/A
- Revenue
- RIGL $203,077,000.00
- SIBN $176,601,000.00
- Revenue This Year
- RIGL $14.41
- SIBN $19.48
- Revenue Next Year
- RIGL $15.97
- SIBN $16.86
- P/E Ratio
- RIGL $9.06
- SIBN N/A
- Revenue Growth
- RIGL 70.16
- SIBN 22.60
- 52 Week Low
- RIGL $8.61
- SIBN $11.70
- 52 Week High
- RIGL $29.82
- SIBN $20.05
- Technical
- Relative Strength Index (RSI)
- RIGL 46.34
- SIBN 43.88
- Support Level
- RIGL $18.63
- SIBN $17.94
- Resistance Level
- RIGL $19.61
- SIBN $18.87
- Average True Range (ATR)
- RIGL 0.79
- SIBN 0.67
- MACD
- RIGL 0.01
- SIBN -0.09
- Stochastic Oscillator
- RIGL 45.15
- SIBN 34.77
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.